Hey dumb dumb... who gave the readers a PERFECT trade before the bell? And even adjusted it to MORE PERFECT. Who's your daddy Stoney?! And you wonder why we get 350K clicks. Right there babe. #1 at GBA for a reason.
Stoney... it is too funny. I knew you'd be crowing about it today when I saw it was up so much... and I was even gonna, AND I AM, gonna pay you a compliment... but you know what's funny.... I WAS GONNA WRITE "8 is YOUR LUCKY NUMBER" Not because of whatever the price was when you wrote that, but because (I thought) in the Old Testament the Ark was 88 QBTS. I just looked, I was wrong, it was 300 cubits... and I have no idea where I got 88 from.... but I swear on my life I had every intention of writing that when I logged on. All afternoon I was thinking QBITS/cubits ----> 88. Because of Noahs Ark. Where'd I get 88 from? Hmph. I usually don't mess up numbers. Oh well. Good job. No denying it sky-rocketed. But still I could have swore it was 88 cubits in the Ark. Hmph.
Good Smoky Morning. Folks the air quality in NYC was the worst in the world yesterday<--- The world that includes Mumbai ./ Really scary.- In Islam, eight is the number of angels carrying the throne of Allah Ba Means fa- What Are the Lucky Numbers in China? Number 8 In China, it is customary to regard even numbers as being more auspicious than odd ones. So, gifts are given in even numbers for the celebration of all occasions. No. 8 has long been regarded as the luckiest number in Chinese culture. With pronunciation of 'Ba' in Chinese, no. 8 sounds similar to the word 'Fa', which means to make a fortune. It contains meanings of prosperity, success and high social status too, so all business men favor it very much. Moreover, in some areas of China, people prefer to pay much more money for a telephone number with 8 in it. They also favor residences on the eighth floor of buildings. In 1990s, a vehicle identification number with 8 was once auctioned off for 5 million Hong Kong dollars.
-Bloom Energy, Perenco to deploy solid oxide fuel cells in U.K. 07:06 BE -Coya reports additional data showing decrease in neuroinflammation with COYA 301 » 07:03 COYA -Marvell strength attributed to Taiwanese report on Amazon AI chip win 06:53 MRVL -Evolus price target raised to $20 from $17 at Mizuho » 06:45 EOLS
It's a slow day so lets just pick apart the above-- There may be a play here in Coya. Lets Do A Timeline Together-- A) Coya Therapeutics opens at $4.75, IPO priced at combined offering price of $5 » 12/29/22 COYA B) Coya data supports role of T-cells for disease modification in Alzheimer's 01/26/23 COYA Coya Therapeutics announced the recent publication of an article entitled "Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer's Disease" in the peer reviewed journal Acta Neuropathologica Communications. The preclinical study was conducted by Ali Faridar, M.D., of Houston Methodist Hospital , under the leadership of Stanley Appel, M.D., the chair of Coya's Scientific Advisory Board. "These data further support that enhancing Treg function is a potential strategy to ameliorate neuroinflammation, which may modify Alzheimer's Disease-associated pathology in the brain. Coya intends to enter a Phase I clinical trial of Treg enhancing biologics for the treatment of neurodegenerative diseases in 2023 with interim data readout anticipated by or before Q1 2024," C) Coya CEO sees year filled with catalysts, milestones ahead 03/02/23 COYA D)Coya Therapeutics reports data from COYA 302 study 03/21 COYA Coya Therapeutics reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to ameliorate disease progression. Four ALS patients with a mean decline of -1.1 points/month in the Revised ALS Functional Rating Scale, or ALSFRS-R, score prior to study initiation, were treated for 48 consecutive weeks with COYA 302 and were evaluated for safety and tolerability, Treg suppressive function, serum biomarkers of oxidative stress and inflammation, and clinical functioning as measured by the ALSFRS-R scale. Following the administration of COYA 302 for 48 weeks, patients were evaluated over an 8-week washout period. During the 48-week treatment period, COYA 302 appeared to be well tolerated. The most common adverse event was mild injection-site reactions. No patient discontinued the study, and no deaths or other serious adverse events were reported. Preliminary efficacy of COYA 302 was measured by the ALSFRS-R scale, a validated rating tool for monitoring the progression of disability in patients with ALS. The mean ALSFRS-R scores at week 24 and week 48 after initiation of treatment with COYA 302 were not statistically different compared to the ALSFRS-R score at baseline, indicating significant amelioration in the progression of the disease over the 48-week treatment period. Treg suppressive function, expressed as percentage of inhibition of proinflammatory T cell proliferation, showed a statistically significant increase over the course of the treatment period and was significantly reduced at the end of the 8-week washout post-treatment period. Treg suppressive function at 24 weeks and 48 weeks were significantly higher compared to baseline, suggesting enhanced and durable Treg suppressive function over the course of treatment. In contrast, Treg suppressive function was significantly decreased at the end of the 8-week washout period compared to end-of-treatment at week 48. The study also evaluated serum biomarkers of inflammation, oxidative stress, and lipid peroxides. The available data up to 16 weeks after initiation of treatment suggest a decrease of these biomarker levels, which is consistent with the observed enhancement of Treg function. The evaluation of the full biomarker data is ongoing. >> Couple thoughts - Very small study! Ok but it is good to be measuring a lack of progression rather than trying to cure something. I think it may be easier. E) After this small study-> Chardan has a Buy rating on the shares with a price target of $9. F) Coya Therapeutics initiated with a Buy at EF Hutton 05/03 COYA EF Hutton initiated coverage of Coya Therapeutics with a Buy rating and $28 price target. Coya, which developed "a pioneering approach to treat neurodegenerative disorders by addressing inflammation in the brain," has found COYA 302 was safe and well tolerated in an initial trial and also demonstrated potential efficacy in boosting Treg cell function and ameliorating progression of amyotrophic lateral sclerosis, or ALS, also called Lou Gehrig's disease. The firm's target is based on after-tax, risk-adjusted net present value of potential future cash flows from the company's ALS program COYA 302, but it notes Coya plans to explore the activity of 302 in other neurodegenerative conditions. G) they picked up a few more trial members-- and release the info Stock is HALTED>>>>>>>>Coya Therapeutics Inc trading resumes 05/16 COYA Coya Therapeutics Inc trading halted, volatility trading pause ->05/16 COYA Coya Therapeutics reports COYA 301 trial resulted in improved cognitive function 05/16 COYA Coya Therapeutics reported results from an open-label proof-of-concept clinical study for COYA 301 in patients with AD. Results of the study will be presented on May 16. The study enrolled eight patients with confirmed presence of brain amyloid pathology and baseline MMSE scores between 12 and 25. The patients were treated with five-day-courses of COYA 301 for four monthly cycles and were followed for two months post-treatment. Treg function and numbers, serum biomarkers of inflammation, and cognitive functioning as measured by the ADAS-Cog, CDR-SB and MMSE assessment tools were evaluated. Clinically, evaluation of cognitive function showed that administration of COYA 301 resulted in a statistically significant improvement in mean MMSE scores during the treatment phase, compared to mean MMSE score at baseline. Consistent with the positive trend in MMSE score, mean scores in ADAS-Cog and CDR-SB scales did not significantly change at the end of treatment with COYA 301, compared to pre-treatment baseline scores, indicating no cognitive decline as measured by these validated instruments. H) 2 days later--> Coya Therapeutics initiated with a Buy at BTIG 05/18 COYA BTIG analyst Thomas Shrader initiated coverage of Coya Therapeutics with a Buy rating and $15 price target. Although the Treg-modulation mechanism "seems space-aged," the technical approach is straightforward with the combination of two validated biologics that might be approved via a streamlined 505(b)(2) pathway, the analyst tells investors in a research note. In addition, Coya's data to date consistently show deep immunomodulation as seen in readouts of both clinical effects and changes in multiple validated biomarkers, says the firm. Ok so we have PT's of $9 & $15...... AND WHERE IS THE STOCK..... $4.23<--------------NOT ANY MOVEMENT!!!!!!!!/ THIS IS THE IPO PRICE. ....... so with all of this knowledge a tiny news story today might now catch your eye.... Coya reports additional data showing decrease in neuroinflammation with COYA 301 » 07:03 COYA THAT is stonedinvesting.-
Coya Therapeutics, Inc. (COYA) NasdaqCM - NasdaqCM Real Time Price. 4.3400+0.1400(+3.33%) At close: 04:00PM EDT 4.5700+0.2300(+5.2995%)<------------ Pre-Market:
$5.94 was the gap up high for COYA on the day pf the stock halt (5/16)-- why this has drifted since I have no idea. Now that $6.00 becomes B/O --
At 3:47 there is a slide that says when treatment stopped progression of ALS continued.... That's pretty big. Only 56 fucking people have seen this vid.. Clearly the Co has a bit of a PR problem-